Petros Pharmaceuticals, Inc. (PTPI) Financial Analysis & Valuation | Quarter Chart
Petros Pharmaceuticals, Inc. (PTPI)
PTPIPrice: $0.01
Fair Value: 🔒
🔒score
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H... more
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. T... more
Description
Shares
| Market Cap | $221,237 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Fady Boctor |
| IPO Date | 2020-12-02 | CAGR | -0.16% |
| Employees | 18 | Website | www.petrospharma.com |
| Div. Yield | — | Payout Ratio | -98.6% |
| Buy Back Yield | 564546357419594029870350336% | Total Yield | 564546357419594029870350336% |
PTPI chart loading...
Fundamentals
Technicals
| Enterprise Value | $-5.36M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-29.01 | EPS Growth 1Y | 130.53% |
| EPS Growth 3Y | -19.52% | EPS Growth 5Y | -79.1% |
| Revenue Growth 1Y | -81.97% | Gross Margin | 0.64% |
| Operating Margin | -18.45% | Profit Margin | -9.68% |
| ROE | 3.04% | ROA | -1.15% |
| ROCE | -3.97% | Current Ratio | 2.22 |
| Quick Ratio | 2.22 | Cash Ratio | 2.2 |
| Debt/Equity | — | Interest Coverage | -79.91 |
| Altman Z Score | -32.46 | Piotroski Score | 3 |